285 related articles for article (PubMed ID: 15574200)
1. CpG methylation of the FHIT, FANCF, cyclin-D2, BRCA2 and RUNX3 genes in Granulosa cell tumors (GCTs) of ovarian origin.
Dhillon VS; Shahid M; Husain SA
Mol Cancer; 2004 Dec; 3():33. PubMed ID: 15574200
[TBL] [Abstract][Full Text] [Related]
2. The contribution of genetic and epigenetic changes in granulosa cell tumors of ovarian origin.
Dhillon VS; Aslam M; Husain SA
Clin Cancer Res; 2004 Aug; 10(16):5537-45. PubMed ID: 15328194
[TBL] [Abstract][Full Text] [Related]
3. [Correlation between methylation of 5'-CpG islands and inactivation of FHIT gene in cervical cancer].
Shi HR; Wu QH; Suo ZH; Nesland JM
Ai Zheng; 2005 Jan; 24(1):7-11. PubMed ID: 15642192
[TBL] [Abstract][Full Text] [Related]
4. Frequent loss of RUNX3 expression by promoter hypermethylation in gastric carcinoma.
Oshimo Y; Oue N; Mitani Y; Nakayama H; Kitadai Y; Yoshida K; Ito Y; Chayama K; Yasui W
Pathobiology; 2004; 71(3):137-43. PubMed ID: 15051926
[TBL] [Abstract][Full Text] [Related]
5. Promoter methylation of cyclin D2 gene in gastric carcinoma.
Oshimo Y; Nakayama H; Ito R; Kitadai Y; Yoshida K; Chayama K; Yasui W
Int J Oncol; 2003 Dec; 23(6):1663-70. PubMed ID: 14612939
[TBL] [Abstract][Full Text] [Related]
6. Promoter methylation and loss of coding exons of the fragile histidine triad (FHIT) gene in intrahepatic cholangiocarcinomas.
Foja S; Goldberg M; Schagdarsurengin U; Dammann R; Tannapfel A; Ballhausen WG
Liver Int; 2005 Dec; 25(6):1202-8. PubMed ID: 16343073
[TBL] [Abstract][Full Text] [Related]
7. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
8. The expression of DNA methyltransferases and methyl-CpG-binding proteins is not associated with the methylation status of p14(ARF), p16(INK4a) and RASSF1A in human lung cancer cell lines.
Sato M; Horio Y; Sekido Y; Minna JD; Shimokata K; Hasegawa Y
Oncogene; 2002 Jul; 21(31):4822-9. PubMed ID: 12101420
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation.
Padar A; Sathyanarayana UG; Suzuki M; Maruyama R; Hsieh JT; Frenkel EP; Minna JD; Gazdar AF
Clin Cancer Res; 2003 Oct; 9(13):4730-4. PubMed ID: 14581343
[TBL] [Abstract][Full Text] [Related]
10. Promoter hypermethylation of RASSF1A and RUNX3 genes as an independent prognostic prediction marker in surgically resected non-small cell lung cancers.
Yanagawa N; Tamura G; Oizumi H; Kanauchi N; Endoh M; Sadahiro M; Motoyama T
Lung Cancer; 2007 Oct; 58(1):131-8. PubMed ID: 17606310
[TBL] [Abstract][Full Text] [Related]
11. GATA-4 regulates Bcl-2 expression in ovarian granulosa cell tumors.
Kyrönlahti A; Rämö M; Tamminen M; Unkila-Kallio L; Butzow R; Leminen A; Nemer M; Rahman N; Huhtaniemi I; Heikinheimo M; Anttonen M
Endocrinology; 2008 Nov; 149(11):5635-42. PubMed ID: 18653721
[TBL] [Abstract][Full Text] [Related]
12. Expression of RUNX3 gene, methylation status and clinicopathological significance in breast cancer and breast cancer cell lines.
Jiang Y; Tong D; Lou G; Zhang Y; Geng J
Pathobiology; 2008; 75(4):244-51. PubMed ID: 18580070
[TBL] [Abstract][Full Text] [Related]
13. Frequent silencing of fragile histidine triad gene (FHIT) in Burkitt's lymphoma is associated with aberrant hypermethylation.
Hussain A; Gutiérrez MI; Timson G; Siraj AK; Deambrogi C; Al-Rasheed M; Gaidano G; Magrath I; Bhatia K
Genes Chromosomes Cancer; 2004 Dec; 41(4):321-9. PubMed ID: 15384174
[TBL] [Abstract][Full Text] [Related]
14. Loss of fragile histidine triad gene expression in advanced lung cancer is consequent to allelic loss at 3p14 locus and promoter methylation.
Wali A; Srinivasan R; Shabnam MS; Majumdar S; Joshi K; Behera D
Mol Cancer Res; 2006 Feb; 4(2):93-9. PubMed ID: 16513840
[TBL] [Abstract][Full Text] [Related]
15. Peripheral blood DNA methylation detected in the BRCA1 or BRCA2 promoter for sporadic ovarian cancer patients and controls.
Bosviel R; Michard E; Lavediaux G; Kwiatkowski F; Bignon YJ; Bernard-Gallon DJ
Clin Chim Acta; 2011 Jul; 412(15-16):1472-5. PubMed ID: 21557934
[TBL] [Abstract][Full Text] [Related]
16. Promoter hypermethylation profile of kidney cancer.
Dulaimi E; Ibanez de Caceres I; Uzzo RG; Al-Saleem T; Greenberg RE; Polascik TJ; Babb JS; Grizzle WE; Cairns P
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):3972-9. PubMed ID: 15217927
[TBL] [Abstract][Full Text] [Related]
17. Possible involvement of RUNX3 silencing in the peritoneal metastases of gastric cancers.
Sakakura C; Hasegawa K; Miyagawa K; Nakashima S; Yoshikawa T; Kin S; Nakase Y; Yazumi S; Yamagishi H; Okanoue T; Chiba T; Hagiwara A
Clin Cancer Res; 2005 Sep; 11(18):6479-88. PubMed ID: 16166423
[TBL] [Abstract][Full Text] [Related]
18. Remodeling epigenetic modifications at tumor suppressor gene promoters with bovine oocyte extract.
Wang Z; Yue Y; Han P; Sa R; Ren X; Wang J; Bai H; Yu H
Cytotherapy; 2013 Sep; 15(9):1164-73. PubMed ID: 23800731
[TBL] [Abstract][Full Text] [Related]
19. Spreading of methylation within RUNX3 CpG island in gastric cancer.
Homma N; Tamura G; Honda T; Matsumoto Y; Nishizuka S; Kawata S; Motoyama T
Cancer Sci; 2006 Jan; 97(1):51-6. PubMed ID: 16367921
[TBL] [Abstract][Full Text] [Related]
20. The methylation status and protein expression of CDH1, p16(INK4A), and fragile histidine triad in nonsmall cell lung carcinoma: epigenetic silencing, clinical features, and prognostic significance.
Nakata S; Sugio K; Uramoto H; Oyama T; Hanagiri T; Morita M; Yasumoto K
Cancer; 2006 May; 106(10):2190-9. PubMed ID: 16598757
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]